🇺🇸 FDA
Patent

US 11564930

RIP1 inhibitory compounds and methods for making and using the same

granted A61KA61K31/553A61P

Quick answer

US patent 11564930 (RIP1 inhibitory compounds and methods for making and using the same) held by Rigel Pharmaceuticals, Inc. expires Mon Jan 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Rigel Pharmaceuticals, Inc.
Grant date
Tue Jan 31 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
55
CPC classes
A61K, A61K31/553, A61P, A61P37/00